Etiology of Travelers' Diarrhea in Australian Tourists Traveling to Southeast Asia
Launched by LUMEN BIOSCIENCE, INC. · Apr 9, 2024
Trial Information
Current as of September 07, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at the causes and frequency of diarrhea among Australian tourists traveling to Southeast Asia. The study will focus on adults who are planning to visit countries like Cambodia, Indonesia, and Thailand for 14 to 28 days. By understanding more about travelers' diarrhea, the researchers hope to improve treatments and preventive measures for future travelers.
To join the study, participants need to be at least 18 years old, currently living in Australia, and have a trip planned to one of the selected Southeast Asian countries within the next month. They should also be willing to complete all study activities, which will continue for about 28 days after their trip. It's important that participants have access to a smartphone and mobile service while traveling so they can stay connected throughout the study. If someone is interested, they will need to give their permission to take part in the research.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Adult aged \> 18 years residing in Australia.
- • Planned travel for 14 to 28 days starting in the next 30 days to selected countries in Southeast Asia, including Cambodia, Indonesia, Laos, Malaysia, Myanmar, the Philippines, Thailand, Timor-Leste, and Vietnam.
- • Willing to participate in the clinical study and available for all planned study activities through approximately 28 days post-travel.
- • Access to a smartphone and mobile phone services while traveling (either by local SIM card, WiFi, or international roaming service on the individual's home-country mobile phone).
- Exclusion Criteria:
- • Unable or unwilling to provide adequate informed consent.
About Lumen Bioscience, Inc.
Lumen Bioscience, Inc. is an innovative biotechnology company specializing in the development of therapeutic and diagnostic solutions leveraging its proprietary platform for producing biologics in engineered algae. Focused on addressing significant unmet medical needs, Lumen Bioscience harnesses the unique properties of microalgae to create safe and effective treatments, particularly in the fields of gastrointestinal diseases and infectious agents. Committed to advancing patient care through rigorous research and clinical trials, the company aims to transform the landscape of biopharmaceuticals with its sustainable and scalable production methods.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Melbourne, , Australia
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported